OncoScreen PSA

The PSA Prostate-Specific Antigen Semi-Quantitative Ultra Rapid Test Device (Whole Blood/Serum/Plasma) is a rapid chromatographic immunoassay designed for the semi-quantitative detection of Prostate-Specific Antigen (PSA) in whole blood, serum, or plasma. PSA is a single-chain glycoprotein with a molecular weight of approximately 34 kDa, secreted primarily by prostate glandular and endothelial cells. In the bloodstream, PSA exists in three major forms: free PSA, PSA bound to α1-antichymotrypsin (PSA-ACT), and PSA complexed with α2-macroglobulin (PSA-MG). While trace amounts of PSA may be present in various male urogenital tissues, only the prostate actively secretes it. Normal serum PSA levels in healthy men typically range from 0.1 to 2.6 ng/mL. Elevated PSA levels may indicate malignant conditions such as prostate cancer or benign conditions including benign prostatic hyperplasia (BPH) and prostatitis. PSA levels between 4–10 ng/mL fall within the diagnostic “gray zone,” while levels above 10 ng/mL are highly indicative of cancer. Recent clinical studies suggest that lowering the screening threshold from 4 to 3 ng/mL can increase prostate cancer detection by 13.2%. The PSA Ultra Rapid Test utilizes a combination of colloidal gold conjugates and anti-PSA antibodies to selectively detect all three major forms of PSA, with a cut-off value of 3 ng/mL and a reference value of 10 ng/mL. It is considered one of the most valuable tools available for the early detection and monitoring of prostate cancer and related prostate conditions.